
Multiple Sclerosis - Pipeline Insight, 2024
Description
Multiple Sclerosis - Pipeline Insight, 2024
DelveInsight’s, “Multiple Sclerosis - Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in Multiple Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Multiple Sclerosis: Overview
Multiple Sclerosis (MS) is a chronic disease of the central nervous system, characterized by the immune system attacking the myelin sheath, the protective covering of nerve fibers. This autoimmune response leads to inflammation and damage, disrupting communication between the brain and the rest of the body. The exact cause of MS is unknown, but it is believed to result from a combination of genetic predisposition and environmental factors such as viral infections, vitamin D deficiency, and smoking. MS typically manifests between the ages of 20 and 50 and is more prevalent in women.
There are several types of MS, with Relapsing-Remitting MS (RRMS) being the most common. RRMS is marked by episodes of new or worsening symptoms followed by periods of remission. Other forms include Secondary Progressive MS (SPMS), which evolves from RRMS and involves a steady progression of symptoms, and Primary Progressive MS (PPMS), which is characterized by a gradual worsening of symptoms from the onset without early relapses. Progressive-Relapsing MS (PRMS) is rare and involves steady progression combined with acute relapses.
Symptoms of MS are diverse and can range from mild to severe, affecting physical, cognitive, and emotional functions. Common symptoms include fatigue, difficulty walking, numbness or tingling, muscle weakness, vision problems, dizziness, bladder and bowel issues, cognitive difficulties, and mood changes. These symptoms can significantly impact daily life and vary widely among individuals, making MS a highly unpredictable disease.
Diagnosing MS involves a thorough medical history, neurological examinations, and various tests such as MRI scans to detect brain and spinal cord lesions, lumbar punctures to analyze cerebrospinal fluid, and evoked potential tests to measure electrical activity in the brain. Despite these tools, diagnosis can be challenging due to the variability of symptoms and the need to rule out other conditions.
While there is no cure for MS, treatment focuses on managing symptoms, reducing relapse frequency, and slowing disease progression. Disease-Modifying Therapies (DMTs) play a crucial role in altering the disease course, while symptomatic treatments and rehabilitation therapies help manage specific issues and maintain function. Lifestyle adjustments, including regular exercise, a healthy diet, and stress management, are also beneficial. With early diagnosis and effective management, many individuals with MS can lead active and fulfilling lives despite the challenges posed by the disease.
""Multiple Sclerosis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple Sclerosis pipeline landscape is provided which includes the disease overview and Multiple Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Multiple Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Multiple Sclerosis.
This segment of the Multiple Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Multiple Sclerosis Emerging Drugs
- IMU-838: Immunic
- Masitinib: AB Science
- Foralumab: Tiziana Life Sciences
- IMCY-0141: ImCyse
- BMS-986353: Bristol-Myers Squibb
Further product details are provided in the report……..
Multiple Sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Multiple Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Multiple Sclerosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Multiple Sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multiple Sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple Sclerosis drugs.
Multiple Sclerosis Report Insights
- Multiple Sclerosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Multiple Sclerosis drugs?
- How many Multiple Sclerosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple Sclerosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple Sclerosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Multiple Sclerosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- ImCyse
- Lucid Psycheceuticals
- Immune Response BioPharma
- Guangzhou Lupeng Pharmaceutical
- Kyowa Kirin
- Nura Bio
- ImStem Biotechnology
- Hoffmann-La Roche
- Bristol-Myers Squibb
- Immunic
- AB Science
- Tiziana Life Sciences
- Clene Nanomedicine
- Supernus Pharmaceuticals
- InnoCare Pharma
- Oryzon Genomics
- GeNeuro SA
- AbbVie
- IMCY-0141
- Lucid-MS
- NeuroVax
- LP-168
- KHK4827
- NB-4746
- CC-97540
- IMS-001
- RO7121932
- BMS-986196
- IMU-838
- Masitinib
- Foralumab
- CNM-Au8
- Botulinum toxin B
- Orelabrutinib
- Vafidemstat
- Temelimab
- Elezanumab
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Multiple Sclerosis: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Multiple Sclerosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- IMU-838: Immunic
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Foralumab: Tiziana Life Sciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- BMS-986353: Bristol-Myers Squibb
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Product Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Multiple Sclerosis Key Companies
- Multiple Sclerosis Key Products
- Multiple Sclerosis- Unmet Needs
- Multiple Sclerosis- Market Drivers and Barriers
- Multiple Sclerosis- Future Perspectives and Conclusion
- Multiple Sclerosis Analyst Views
- Multiple Sclerosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.